NeXT Personal, an advanced, personalized, and tumor-informed liquid biopsy assay, is designed to detect molecular residual disease (MRD) and cancer recurrence at the earliest timepoints — prior to, during or after treatment — in patients previously diagnosed with cancer.
NeXT Personal, an advanced, personalized, and tumor-informed liquid biopsy assay, is designed to detect molecular residual disease (MRD) and cancer recurrence at the earliest timepoints — prior to, during or after treatment — in patients previously diagnosed with cancer. A unique, multifunctional panel design enables simultaneous variant monitoring over time in addition to MRD, offering an unprecedented look into tumor biology.
NeXT Personal was developed to deliver industry-leading MRD sensitivity in the range of 1-3 parts per million (PPM) representing a 10X-100X increase over other available methods. NeXT Personal is sample sparing, requiring only a single tube of blood (4mL plasma/15ng cfDNA), and 1mm3 of FFPE tumor tissue (Figure 1, 2).
Figure 1: MRD Sensitivity: Targeting Detection at the Earliest Timepoints
Model Assumptions: Median breast tumor size detected by mammography: 1.3cm, Median shedding per NSCLC TRACERx study6; Residual tumor from surgery: 1%; Volume doubling time (actual VAF time): 2 months
Figure 2: NeXT Personal: Advanced, Higher Sensitivity, Personalized, Tumor-Informed Liquid Biopsy for MRD & Variant Tracking
